Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
Article content
Patent-protected aminated tryptamine derivatives strengthen Enveric's leadership in next-generation mental health treatments
Article content
CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives.
Article content
The patented compounds were designed through Enveric's proprietary discovery platform and represent a first-in-class approach to non-hallucinogenic psychedelic-inspired therapeutics. The compounds demonstrated low hallucinogenic liability in preclinical testing, including minimal Head Twitch Response (HTR) and reduced 5-HT2A receptor activation – two established indicators of hallucinogenic activity in rodents.
Article content
'The allowance of this application adds a new tier of patent-protected innovation to our pipeline of non-hallucinogenic neuroplastogens,' said Joseph Tucker, Ph.D., CEO of Enveric. 'Unlike traditional psychedelics that require intensive clinical monitoring due to their hallucinogenic effects, our molecules are designed for frequent, flexible, outpatient dosing, which we expect will be better aligned with patient lifestyles, clinics workflows, and payers established models.'
Article content
Non-hallucinogenic psychedelic analogs represent a critical evolution in the treatment of psychiatric and neurological disorders, with potential to treat conditions like depression, anxiety, PTSD, and cognitive impairment, without the operational limitations of hallucinatory experiences. The patent covers both the molecular compositions and their therapeutic applications, further strengthening Enveric's competitive position in this emerging category.
Article content
'This achievement reflects Enveric's continued execution on its mission to develop safe and effective neuroplastogenic therapeutics,' Dr. Tucker added. 'Each addition to our intellectual property portfolio helps build a more valuable portfolio of assets for long-term growth.'
Article content
The patented molecules were discovered through the Company's proprietary discovery and development platform, which leverages computational and medicinal chemistry to identify optimized, next-generation therapeutic molecules with favorable safety, pharmacology, and scalability profiles.
Article content
About Enveric Biosciences
Article content
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
Article content
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Article content
Article content
Article content
Article content
Contacts
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
Prediction: Solana Will Be Worth $500 Within 5 Years
Key Points Solana is seeing a lot of users actually using its chain for what it was intended to do. That's driving money to the chain itself, as well as into its app ecosystem. Its competitors aren't anywhere near it in terms of how much cash their apps bring in. 10 stocks we like better than Solana › Would you want to invest in a store that gets a lot of paying customers, or one that doesn't? The same principle applies to blockchains, as the chains that collect the most fees are the ones people actually use. Right now the busiest store is Solana, (CRYPTO: SOL) which has raked in more protocol revenue than any other network for three straight quarters and counting. Furthermore, at roughly $150 per coin, its market still prices it like an also-ran rather than a star player. That mismatch between cash coming in and price going out is why I think the token can top $500 within five years. Network revenue and app revenue are winning the day Let's clarify two very important concepts for evaluating cryptocurrencies like Solana: Network revenue, and application revenue. Network revenue is simply the sum of fees users pay to get their transactions registered into a block on the chain. Application revenue, on the other hand, is the sum total of revenue generated by the applications running on a chain. High network and app revenue means heavy activity, in the form of decentralized finance (DeFi) swaps, non-fungible token (NFT) mints, payments for services, and borrowing or lending flows. In the 24 hours leading up to July 8, Solana brought in $1.3 million in network revenue, and its app ecosystem brought in $8.6 million, vastly outclassing all of its competitors by a large margin. This streak has been accelerating in the most recent quarter. Solana booked more than $571 million in app revenue in second-quarter 2025, leaving Ethereum 's $200 million in the dust. Daily snapshots tell the same story. On July 6, Solana captured almost half of all layer 1 (L1) and layer 2 (L2) network earnings worldwide. Why do users keep piling in? Start with transaction costs and speed. A typical Solana transaction costs about $0.00025 and settles in a couple of seconds, compared with Ethereum's multi-dollar gas bills that arrive fashionably late. Those economics make Solana the chain of choice for high-frequency decentralized exchange (DEX) trading, driving 46% of all decentralized-app revenue across crypto last quarter. App developers follow the money, as they won't get paid otherwise. On that front, more than 7,600 new builders joined the ecosystem in 2024, the fastest growth in the sector by far. A bigger dev base seeds more apps, which beget more users, which inflate revenue, making the Solana flywheel exactly what Ethereum pioneered but is now struggling to maintain. Taken together, nine months of revenue leadership signal that Solana owns the most vibrant storefront in crypto. Next comes turning that cash register ring into price appreciation, which will take time. The path to $500 is very plausible from here Given the above, the odds of Solana growing significantly over the coming years are fairly favorable. Hitting a target of $500 from $152 requires a 229% climb, or roughly a 3.3x return from where the coin is today. That sounds heroic until you remember that Solana traded near $260 in late 2021, with far less adoption than today, and with practically zero in terms of its DeFi application revenue. Assuming network revenue keeps compounding while fee-burn mechanics retire a slice of every transaction cost, the float of available tokens will tighten over time, pushing the price lever upward. Speed and cost aren't the only draws. Solana's single-shard architecture lets every smart contract and program see the same state at once, cutting the complexity of cross-chain bridges that have plagued rivals with hacks and downtime. If big-ticket real world asset (RWA) platforms or AI inference markets pick a chain for throughput reasons, Solana's capacity to process 65,000 transactions per second (TPS) makes it a frontrunner. Still, five years is plenty of time for potholes along the way. A hard regulatory crackdown on low-fee chains, a catastrophic validator outage, or Ethereum's long-awaited darksharding upgrade could all erode Solana's edge. Macro shocks matter, too. If liquidity vanishes from the market, fee revenue will follow it down for both its apps and the network itself. Even so, the core thesis is simple. Money talks. When a chain out-earns everyone else for nine straight months, the market usually notices eventually. If Solana's revenue keeps sprinting while its tokenomics quietly throttle supply, a triple-digit price tag starting with "5" is no stretch whatsoever over the next few years. In fact, I predict that it'll happen before 2030, because right now, its competitors simply can't keep up with its main draws. Should you invest $1,000 in Solana right now? Before you buy stock in Solana, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Solana wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor 's total average return is1,047% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 7, 2025
National Post
42 minutes ago
- National Post
EU to suspend U.S. tariff retaliation, will look for a deal with Trump by Aug. 1
The European Union will suspend retaliatory tariffs on U.S. goods scheduled to take effect Monday in hopes of reaching a trade deal with the Trump administration by the end of the month. Article content ″This is now the time for negotiations,″ European Commission President Ursula von der Leyen told reporters in Brussels on Sunday, after President Donald Trump sent a letter announcing new tariffs of 30 per cent on goods from the EU and Mexico starting Aug. 1. Article content Article content Article content The EU — America's biggest trading partner and the world's largest trading bloc — had been scheduled to impose ″countermeasures″ starting Monday at midnight Brussels time (6 p.m. EDT; 22:00 GMT). The EU negotiates trade deals on behalf of its 27 member countries. Article content Von der Leyen said those countermeasures would be delayed until Aug. 1, and that Trump's letter shows ″that we have until the first of August″ to negotiate. Article content ″We have always been clear that we prefer a negotiated solution,″ she said. If they can't reach a deal, she said that ″we will continue to prepare countermeasures so we are fully prepared.″ Article content A 30% tariff on EU exports would hurt businesses, consumers and patients on both sides of the Atlantic. We will continue working towards an agreement by August 1. At the same time, we are ready to safeguard EU interests on the basis of proportionate countermeasures. — Ursula von der Leyen (@vonderleyen) July 12, 2025 Article content Europe's biggest exports to the U.S. are pharmaceuticals, cars, aircraft, chemicals, medical instruments and wine and spirits. Article content Italian Foreign Minister Antonio Tajani was heading to Washington for talks Monday with the U.S. administration and Congress. In a statement, Tajani's office said that in his talks with EU allies before the meetings, he stressed the need to 'negotiate with one's head held high.' Article content The right-wing government of Premier Giorgia Meloni, the only EU leader to attend Trump's inauguration, has sought to position itself as a ' bridge' between Brussels and Washington. Article content Trump has said his global tariffs would set the foundation for reviving a U.S. economy that he claims has been ripped off by other nations for decades. Trump, in his letter to the EU, said the U.S. trade deficit was a national security threat. Article content Trump isn't satisfied with some of the draft agreements on trade, White House National Economic Council Director Kevin Hassett said on ABC News Sunday.
CTV News
44 minutes ago
- CTV News
Canada relies on foreign regulators for the majority of drug manufacturer inspections — but one of its biggest partners is falling behind
New data obtained by CTV News from Health Canada shows that 85 per cent of inspections of drug manufacturing sites supplying the Canadian market were conducted by international regulators—not Health Canada. (Guteksk7 / Getty Images) Drug manufacturers are tasked with formulating and producing the medications millions of Canadians take each day, from antibiotics to blood pressure medications. We trust them to stick to strict standards — because quality issues can compromise treatments, worsen health outcomes, and in the most severe cases, make patients seriously ill. New data obtained by CTV News from Health Canada shows that 85 per cent of inspections of drug manufacturing sites supplying the Canadian market were conducted by international regulators — not Health Canada. Given the scale and complexity of the global pharmaceutical supply chain for both brand name and generic drugs, reliance on partners is necessary. But the United States, which Canada relies on for 70 per cent of these inspections, has been facing an inspection backlog and remains behind its pre-pandemic inspection levels. Experts are raising concerns about how well the system can safeguard Canadians from substandard or dangerous medications. US FDA logo A U.S. Food and Drug Administration building is seen behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md., on Aug. 2, 2018. (AP Photo/Jacquelyn Martin, File) David Ridley is a health economist at Duke University in North Carolina who has studied the U.S. Food and Drug Administration (FDA) drug manufacturer inspection system in the United States. He said recent cuts to the regulator as part of the Department of Government Efficiency (DOGE) 'are disruptive and very stressful for FDA staff, but the problems with inspections date back for years, even decades.' 'Many of these establishments are not being inspected by Canadian or U.S. officials,' said Ridley. He warns of the risks of lax oversight, and 'we might get low quality products, products that don't work as well, aren't as stable, and in a very worst-case scenario…are toxic.' U.S. inspections took a nosedive during the pandemic. Last year the Associated Press reported that nearly 2,000 drug plants were overdue for inspections. The U.S. Government Accountability Office, an independent government agency that audits government activities at the request of congressional committees, has flagged the area of drug supply chain oversight as 'high risk' since 2009. The office said in a 2024 report that it 'has had long-standing concerns about FDA's ability to oversee the increasingly global drug supply chain.' Matthew Herder, professor of law and medicine at Dalhousie University, specializes in the regulation of pharmaceuticals in Canada. He said knowledge that the biggest and most sophisticated regulator in the world is thin on the ground could potentially encourage lax practices. 'I worry that people will start to cut corners,' said Herder. Past failures reveal the stakes The drugs Canadians take are manufactured around the world. In 2024, 30.8 per cent of Canada's pharmaceutical imports originated from the United States, at least 33.5 per cent from European countries, 3.2 per cent from India, and 2.9 per cent from China — according to trade data from Statistics Canada. Over the years the industry has been dogged with a series of safety lapses. In 2023, eye drops manufactured in India were recalled after contamination with drug resistant bacteria was discovered. The products were traced to three deaths and eight cases of blindness in the United States, according to the New York Times. Eye drops A selection of eye drops line a shelf at a pharmacy in Los Angeles on Dec. 12, 2023. Repeated recalls of eyedrops were drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas. Unlike prescription drugs, eyedrops and other over-the-counter products don't get preliminary review by the FDA. (AP Photo/Richard Vogel) The FDA reported more than 100 people died after taking a common blood thinner that was recalled in 2007 due to contamination with an unnatural chemical during manufacturing in China. Reporter Katherine Eban's 2019 book Bottle of Lies chronicled profit-motivated fraud and deceit at Indian generic pharmaceutical company Ranbaxy in a decade-long investigation. In recent years in Canada, drugs have been recalled for manufacturing issues like microbial and latex contamination. Mina Tadrous, the Canada research chair in real-world evidence and pharmaceutical policy and an associate professor at University of Toronto, estimates that the 2018 recall of valsartan for nitrosamine impurities (considered probable human carcinogens) led 200,000 patients to switch prescriptions in a single month in Canada. The recall rippled through the health care system causing disruptions for patients, doctors and pharmacists. While toxic contamination is a worst-case scenario, the most common impact is more insidious, said Ridley. 'If the product is low quality, the most likely outcome is it's just not going to be as effective. And that's going to be really hard for people to notice.' Ineffective prescription drugs can lead to failed treatments, prolonged illness, drug resistance, and a loss of trust in healthcare. 'Pharmacists count on a strong regulatory system to make sure medications are safe and high-quality,' said Tyler Gogo, senior manager of communications at the Canadian Pharmacists Association in an emailed statement. He said when that system falls short, 'it can cause real problems in delivering care.' Reliance on foreign regulators As of March 31, 2025, Canada's drug supply relied on 927 facilities within the country and 5,024 located abroad. Last fiscal year, Health Canada conducted 312 domestic onsite inspections, 47 foreign onsite inspections and relied on information from trusted international regulatory partners like the FDA, for another 2086 site inspections. Like the United States, Canada halted international inspections in 2020 due to pandemic-related travel restrictions. While the inspections resumed, they did not increase to make up for the missed year. However, Health Canada said it does not have any backlogs for planned inspections. 'That's the strength of the reliance model,' said Kim Godard, Director General, Health Product Compliance Directorate at Health Canada, 'everyone kind of pitches in, we're not in the same situation in terms of creating huge backlogs.' The number of facilities and the scope of the industry outstrips the resources of any single regulator. 'It makes sense to rely on partners,' said Ridley. 'The FDA is so big and the United States is so big. We have the scale. It does make sense to partner with us. But that's conditional on being able to count on us to make those foreign trips.' But Ridley said the U.S. has struggled to staff foreign offices in India and China, major sources of active ingredients in drugs. Regarding the situation in the United States, Health Canada's Godard said 'there's no concern right now in Canada.' She said if a site is particularly important, gaps will be filled in by Canadian inspectors or another partner like Australia. Industry pressures and generic drugs Concerns about inspection protocols come at a time when parts of the industry are under increasing pressure to produce drugs more cheaply. 'I worry most about generic manufacturers because they are in this race to the bottom with their competitors,' said Ridley. He said major U.S. drug purchasers, retailers and wholesalers are looking for the cheapest generic. Generic manufacturers in Canada face similar pressures. 'There's a potential disconnect between how we pay for drugs and our supply chain,' said Tadrous. He said though many hospitals look closely at where they source medications from, drug selection processes in Canada haven't always considered how or where a drug is made. 'For a very long period of time they have been agnostic to how drugs enter the country and the regulator and the payers have sort of been separate,' he said. Generics make up about 20 per cent of product sales by value and 75 per cent of the market share by prescriptions in Canada, according to IQVIA Pharmafocus 2027, a global forecast on pharmaceutical trends used by Health Canada. Expanded national pharmacare is likely to increase demand for generics. Last year Health Canada recalled three generic drugs (Accel-Ondansetron ODT, Mint-Betahistine and PMS-Pirfenidone) due to serious data integrity issues found at India-based Synapse Labs, the site that had tested the products. The European Medicines Agency identified 'irregularities in study data,' raising serious concerns about the bioequivalence of the drugs. Following the recall, the makers of Accel-Ondansetron ODT and Mint-Betahistine submitted new bioequivalence data, according to Health Canada. The regulator concluded the drugs to be safe and equivalent to the brand-name drugs and has granted approval for them to resume selling the products. When asked if industry pressures in the generics space was a concern the department said, 'Health Canada has not identified significant ongoing compliance concerns specific to generic drug manufacturers.' Despite concerns about oversight gaps and mounting pressure on regulators around the world, Health Canada said it is actively adapting. 'We're following the context, we're following the trends, we're following the technologies, we're following what's happening in the pharmaceutical industry to make sure that we're able to meet the demands of tomorrow,' said Godard.
